CD8A and neoplasm: Cell depletion using antibodies against CD4, CD8, and NK1.1 in the MC38 tumor model showed that the therapeutic efficacy of this IL-36γ-armed OV depended on both CD4+ and CD8+ T cells, and partially on NK cells.